PPARG and type 2 diabetes mellitus: In various rodent models of type 2 diabetes (db/db mice, obese Zucker rats, and OLETF rats), treatment with thiazolidinedione (TZD)–a high-affinity synthetic ligand for PPARγ –not only improves insulin resistance and glycemic control, but also ameliorates diabetic nephropathy by inhibiting glomerular hypertrophy, reducing mesangial matrix expansion, and improving proteinuria and renal function [2].